MSFrontier

DHAME

Effects of Therapeutic Exercise and Long-term Docosahexaenoic Acid (DHA) Supplementation on Physical, Physiological, Motor, Mental, and Cognitive Variables in Patients With Multiple Sclerosis.
Enrolling by invitationNot a drug-phase studyMS (type not specified)NCT07346703

What it found

Still running

No result yet.

What was tested

Treatment tested

  • Omega-3 fatty acids
  • Docosahexaenoic Acid (DHA) Dietary Supplement

Placebo or sham

  • Sunflower Oil

What it measured

Main measures

  • ISOKINETIC

    Throughout study completion, an average of 12 weeks

    Physical function

Other measures (11)

  • Modified Fatigue Impact Scale

    Throughout study completion, an average of 12 weeks

    Thinking and memoryFatigue

  • MSQoL-54 - Walking Status

    Throughout study completion, an average of 12 weeks

    Walking and mobilityQuality of life (reported by participants)

  • MSQoL-54 - Days Unable to Work or Attend School Due to Health

    Throughout study completion, an average of 12 weeks

    Quality of life (reported by participants)

  • MSQoL-54 - Hospital Admission in the Previous Year

    Throughout study completion, an average of 12 weeks

    Quality of life (reported by participants)

  • MSQoL-54 - Depressive Symptoms

    Throughout study completion, an average of 12 weeks

    Mood and sleepQuality of life (reported by participants)

  • THERMOGRAPHY

    Pre, six weeks after the start and after the intervention (12 weeks)

  • SIT TO STAND TEST

    Throughout study completion, an average of 12 weeks

    Physical function

  • TIME UP AND GO test

    Throughout study completion, an average of 12 weeks

    Walking and mobilityPhysical function

  • HAND GRIP

    Throughout study completion, an average of 12 weeks

    Arm and hand functionPhysical function

  • IL-6

    Pre, six weeks after the start and after the intervention (12 weeks)

    Immune response

Who could take part

MS (type not specified) · 18 to 65

Inclusion Criteria: The patient sample comes from the Multiple Sclerosis Association (AMDEM) of the Murcia region and the neurology department of the Ribera Salud Hospital in Molina de Segura. Patients diagnosed with multiple sclerosis according to the McDonald criteria, aged between 18 and 65 (approximately), who have not suffered any flare-ups in the previous month and who have a score of 0.00 to 6 on the Expanded Disability Status Scale (EDSS) and are able to activate the tibialis anterior muscle will be eligible for the study. Exclusion Criteria: * Not fulfilling the inclusion criteria. * Having any problems performing the tests. * Having any problems taking the supplement or placebo.

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

This clinical trial will investigate the effects of combining therapeutic exercise with DHA supplementation in 100 patients with multiple sclerosis using a randomized controlled design. Participants, diagnosed according to the McDonald criteria, will undergo functional, cognitive, fatigue, and quality-of-life assessments through tools such as the EDSS, BRB-N, MFIS, EVA-f, and MSQoL-54. Physiological evaluations will include infrared thermography, isokinetic strength testing, perceived exertion (Modified Borg Scale), balance (Timed Up and Go), lower-limb power (Sit-to-Stand app), and handgrip strength. The study hypothesizes that this combined intervention will improve motor function, cognition, fatigue management, and overall quality of life by enhancing neuromuscular activation and metabolic efficiency.

Loading reviews and guidelines…

Related trials

History

    1. Started

      Jan 2026

    2. Main results due

      Jun 2026

    3. Finished

      Jul 2026

    Assembled by software from public sources and not checked by people. Each record links to its source. Report an error